研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences,Beijing,China,100021[3]Beijing Tongren Hospital,Beijing,China[4]Peking Union Medical College Hospital,Beijing,China[5]Chongqing Cancer Hospital,Chongqing,Chongqing,China,404100[6]Fujian Cancer Hospital,Fuzhou,Fujian,China[7]Gansu Province Tumor Hospital,Lanzhou,Gansu,China[8]Sun Yat-Sen University Cancer Center,Guozhou,Guangdong,China[9]Harbin medical university affiliated tumor hospital,Harbin,Heilongjiang,China[10]Henan Province Tumor Hospital,Luoyan,Henan,China[11]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[12]Hunan Province Tumor Hospital,Changsha,Hunan,China[13]Jiangsu province tumor hospital,Nanjing,Jiangsu,China[14]Jilin Cancer Hospital,Changchun,Jilin,China[15]Liaoning Province Tumor Hospital,Shenyang,Liaoning,China[16]Cancer Hospital of Fudan University,Shanghai,Shanghai,China[17]West China Hospital Of Sichuan University,Chongqing,Sichuan,China,400010[18]20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital .,Tianjin,China,300600[19]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China[20]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022
研究目的：
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.
